25C-NBOMe: Difference between revisions

>David Hedlund
m not in PiHKAL
>David Hedlund
{{#set:Featured=true}}
 
(40 intermediate revisions by 16 users not shown)
Line 1: Line 1:
<br />
{{headerpanel|{{Warning/25C-NBOMe}}}}
{{headerpanel|{{Warning/25C-NBOMe}}}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/25C-NBOMe}}
{{SubstanceBox/25C-NBOMe}}
'''25C-NBOMe''' (also known as '''Cimbi-82''', '''NBOMe-2C-C''' and '''2C-C-NBOMe''') is a novel [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] class. It is a member of the 25x-NBOMe series, a recently discovered group of potent psychedelic compounds derived from the [[2C-x]] family.


'''25C-NBOMe''' (also known as '''Cimbi-36''', '''2C-C-NBOMe''', and '''"N-Bomb"''', although this term is used broadly to refer to the entire [[25x-NBOMe]] family) is a novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].  
The name 25C-NBOMe, which is short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-C]]. It was discovered in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">{{cite journal | vauthors=((Heim, R.)) | title=Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts | date= 2004 | url=https://refubium.fu-berlin.de/handle/fub188/11995 | doi=10.17169/refubium-16193}}</ref> and subsequently investigated by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Braden. (2007)">{{cite journal | vauthors=((Braden, M. R.)) | journal=Theses and Dissertations Available from ProQuest | title=Towards a biophysical understanding of hallucinogen action | pages=1–176 | date=1 January 2007 | url=http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 | access-date=8 August 2012}}</ref> It has been studied in its radiolabelled form as a potential ligand for mapping the distribution of serotonin-2A receptors in the brain using positron emission tomography (PET).<ref>{{cite journal | vauthors=((Ettrup, A.)), ((Hansen, M.)), ((Santini, M. A.)), ((Paine, J.)), ((Gillings, N.)), ((Palner, M.)), ((Lehel, S.)), ((Herth, M. M.)), ((Madsen, J.)), ((Kristensen, J.)), ((Begtrup, M.)), ((Knudsen, G. M.)) | journal=European Journal of Nuclear Medicine and Molecular Imaging | title=Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers | volume=38 | issue=4 | pages=681–693 | date= April 2011 | url=http://link.springer.com/10.1007/s00259-010-1686-8 | issn=1619-7070 | doi=10.1007/s00259-010-1686-8}}</ref><ref>{{cite book | vauthors=((Hansen, M.)) | date= 2010 | title=Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain: PhD Thesis | publisher=Faculty of Pharmaceutical Sciences, University of Copenhagen | isbn=9788792719003}}</ref> The first reports of human use appeared in 2010 following its appearance on the online [[research chemical]] market.


The name 25C-NBOMe, which short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-C]]. It was discovered in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).<ref>https://www.ncbi.nlm.nih.gov/pubmed/21174090</ref><ref>http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V</ref>
[[Subjective effects]] include [[stimulation]], [[geometry|open and closed-eye visuals]], [[time distortion]], [[euphoria]], and [[ego loss]]. 25C-NBOMe's effects are sometimes compared to those of [[LSD]] or [[DOx]]. However, it is reported to have stronger visual effects and less cognitive and emotional effects like [[ego loss]] and [[introspection]]. Additionally, 25C-NBOMe is reported to be considerably more stimulating than other psychedelics. Serious side effects are more common and include [[nausea]], [[muscle tension]], [[anxiety]], cardiovascular effects, and [[seizures]].


It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family are not [[orally]] active and should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25C-NBOMe can also be vaporized and inhaled; this is known to cause significantly more rapid and powerful effects and a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range as well as having a low [[therapeutic index]].
It is worth noting that members of the [[25x-NBOMe|NBOMe]] series are not [[orally]] active and should be administered [[sublingual|sublingually]] (by holding it into one's mouth and allowing it to absorb over a period of 15 minutes). 25C-NBOMe can also be vaporized and inhaled for more rapid and powerful effects and a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are active in the microgram range as it significantly increases the risk of overdose. 25C-NBOMe is also sometimes sold as a counterfeit version of LSD due to its similar effects and ability to be laid onto blotter paper.  


This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}} Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe in humans, and it has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood [[psychedelic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.
Very little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe. However, it has been associated with many deaths and hospitalizations which suggests that it has a significantly worse toxicity profile than classical psychedelics like [[LSD]] or [[psilocybin mushrooms]]. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. It is highly advised to use [[harm reduction practices]] if using this substance.
 
[[File:25C-NBOMe blotter.jpg|200px|thumbnail|Blotter paper containing 25C-NBOMe]]


==Chemistry==
==Chemistry==
{{chemistry}}
25C-NBOMe or 2C-C-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as [[2C-C]]. 25C-NBOMe is a substituted phenethylamine with methoxy groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a chlorine atom attached to carbon R<sub>4</sub>. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH<sub>3</sub>O- bound to a benzene ring at R<sub>2</sub>.
25C-NBOMe or 2C-C-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as [[2C-C]]. 25C-NBOMe is a substituted phenethylamine with methoxy groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a chlorine atom attached to carbon R<sub>4</sub>. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH<sub>3</sub>O- bound to a benzene ring at R<sub>2</sub>.


==Pharmacology==
==Pharmacology==
{{pharmacology}}
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
25C-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|partial agonist]].<ref>Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24397362</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.   
25C-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|partial agonist]].<ref>{{cite journal | vauthors=((Hansen, M.)), ((Phonekeo, K.)), ((Paine, J. S.)), ((Leth-Petersen, S.)), ((Begtrup, M.)), ((Bräuner-Osborne, H.)), ((Kristensen, J. L.)) | journal=ACS chemical neuroscience | title=Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists | volume=5 | issue=3 | pages=243–249 | date=19 March 2014 | issn=1948-7193 | doi=10.1021/cn400216u}}</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.   


In comparison to [[2C-C]], the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for [[LSD]].<ref>25C-NBOMe--new potent hallucinogenic substance identified on the drug market (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22989597</ref> In comparison to LSD however it is only a third of the potency.<ref>http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml</ref>
In comparison to [[2C-C]], the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for [[LSD]].<ref>{{cite journal | vauthors=((Zuba, D.)), ((Sekuła, K.)), ((Buczek, A.)) | journal=Forensic Science International | title=25C-NBOMe--new potent hallucinogenic substance identified on the drug market | volume=227 | issue=1–3 | pages=7–14 | date=10 April 2013 | issn=1872-6283 | doi=10.1016/j.forsciint.2012.08.027}}</ref> In comparison to LSD however it is only a third of the potency.<ref>{{Citation | title=Erowid 2C-C-NBOMe Vault : Dose/Dosage | url=https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml}}</ref>


==Subjective effects==
==Subjective effects==
The effects listed below are based upon the [[subjective effect index]] and personal experiences of [[PsychonautWiki]] [[Special:TopUsers|contributors]]. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base


|{{effects/physical|
|{{effects/physical|


*'''[[Effect::Stimulation]]''' and '''[[Effect::Sedation]]''' - In terms of its effects on the subject's physical energy levels, 25C-NBOMe is considered to be energetic and well as sedating, leaving the subject in a state of equilibrium between being stationary and moving. The physical stimulation manifested by this substance can be described as similar to [[2C-B]] , and is commonly experienced as simultaneously easygoing and physically difficult, sometimes presenting overstimulation which results in bodily shakes and teeth grinding. The levels of stimulation can be considered less intense than [[25I-NBOMe]] and the sedation can be considered slightly less intense than other psychedelics such as [[psilocin]] and [[2C-C]].
*'''[[Effect::Stimulation]]''' - 25C-NBOMe is considered to be very energetic and stimulating. The physical stimulation manifested by this substance can be described as similar to [[2C-B]] , and is commonly experienced as simultaneously easygoing and physically difficult, sometimes presenting overstimulation which results in bodily shakes and teeth grinding. The levels of stimulation are reported to be more intense than classical psychedelics but less intense than [[25I-NBOMe]], of which it is described as mildly sedating by comparison.
*'''[[Effect::Mouth numbing]]''' - Assuming the substance has been taken [[sublingual|sublingually]], the very first physical effect which a person will notice immediately after sublingual absorption is a strong, unpleasant metallic chemical taste. This is accompanied by a very obvious feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed. This is the key difference when it comes to determining whether one's blotter paper contains LSD or one of the NBOMe series.
*'''[[Effect::Mouth numbing]]''' - Assuming the substance has been taken [[sublingual|sublingually]], the very first physical effect which a user will notice is a strong, unpleasant metallic chemical taste. This is accompanied by a very obvious feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed. This is the key difference when it comes to determining whether one's blotter paper contains LSD or one of the NBOMe series.
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" itself can be described as a generally mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
*'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" itself can be described as a generally mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
*'''[[Effect::Perception of bodily lightness]]''' - In terms of the body’s perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
*'''[[Effect::Perception of bodily lightness]]''' - In terms of the body’s perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
*'''[[Effect::Tactile hallucinations]]'''  
*'''[[Effect::Tactile hallucination]]'''  
*'''[[Effect::Changes in felt gravity]]''' - Compared to classic [[tryptamines]], this effect is considerably less intense than what is commonly experienced with [[DMT]] and [[Psilocin]].  
*'''[[Effect::Changes in felt gravity]]''' - Compared to classic [[tryptamines]], this effect is considerably less intense than what is commonly experienced with [[DMT]] and [[psilocin]].  
*'''[[Effect::Nausea]]''' - As the user begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this has either happened or the trip begins to fully set in. In comparison to other [[psychedelic]]s such as [[psilocin]], [[LSD]], [[2C-E]] and [[2C-I]], this could actually be very considered very mild in its intensity.
*'''[[Effect::Nausea]]''' - As the user begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this has either happened or the trip begins to fully set in. In comparison to other [[psychedelic]]s such as [[psilocin]], [[LSD]], [[2C-E]] and [[2C-I]], this could actually be very considered very mild in its intensity.
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Abnormal heartbeat]]'''
Line 42: Line 44:
*'''[[Effect::Muscle cramps]]'''
*'''[[Effect::Muscle cramps]]'''
*'''[[Effect::Muscle tension]]'''
*'''[[Effect::Muscle tension]]'''
*'''[[Effect::Gustatory hallucinations]]'''
*'''[[Effect::Gustatory hallucination]]'''
*'''[[Effect::Vasoconstriction]]'''  
*'''[[Effect::Vasoconstriction]]'''  
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]'''
Line 74: Line 76:


====[[Effect::Geometry]]====
====[[Effect::Geometry]]====
The visual geometry that is present throughout this trip is often described as very similar in appearance to that of [[LSD]]. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics, they can be described as significantly more intricate than the visual geometry found within [[2C-I]] and most of the [[2C-x]] family in general as well as completely on par with [[LSD]], [[Psilocin]] and [[DMT]] at appropriately high dosages, which seem lower in proportion to the accompanying physical effects when compared to that of [[25I-NBOMe]].
25C-NBOMe visual geometry is often described as very similar in appearance to that of [[LSD]]. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics, they can be described as significantly more intricate than the visual geometry found within [[2C-I]] and most of the [[2C-x]] family in general as well as completely on par with [[LSD]], [[Psilocin]] and [[DMT]] at appropriately high dosages, which seem lower in proportion to the accompanying physical effects when compared to that of [[25I-NBOMe]].


In terms of their behaviour, 25C-NBOMe’s geometry leads onto [[Effect::Level 8A]] visual geometry with [[Level 8B]] remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelopes the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
The behavior of 25C-NBOMe geometry leads to [[Effect::Level 8A]] visual geometry with [[Level 8B]] remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the user stares at a central point. This eventually envelopes the visual field and creates the sensation that the user has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.


====Hallucinatory states====
====Hallucinatory states====
Line 84: Line 86:


*'''[[Effect::Transformations]]'''
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucinations]]''' - (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') These are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
*'''[[Effect::Internal hallucination]]''' - (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') These are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
*'''[[Effect::External hallucinations]]''' - (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]''). These are often manifesting as rapidly moving, interactive solid and typically asymmetrical matter or physical beings reflecting imagined concepts. They are more common in bright environments and can be described as external in their manifestation, equally lucid and delirious in believability, interactive in style, autonomous in interaction, and almost exclusively alien, mystical, or a transcendental nature in their overall theme.
*'''[[Effect::External hallucination]]''' - (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]''). These are often manifesting as rapidly moving, interactive solid and typically asymmetrical matter or physical beings reflecting imagined concepts. They are more common in bright environments and can be described as external in their manifestation, equally lucid and delirious in believability, interactive in style, autonomous in interaction, and almost exclusively alien, mystical, or a transcendental nature in their overall theme.


}}
}}
|{{effects/cognitive|
|{{effects/cognitive|
 
The cognitive effects of 25C-NBOMe are commonly described as being notably light and underwhelming in comparison to more traditional [[psychedelics]]. It is not uncommon for user to report feeling that their thought stream has maintained a normality in style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to [[25I-NBOMe]].
The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional [[psychedelic]]s. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to [[25I-NBOMe]].
 
The most prominent of these cognitive effects generally include:
 
*'''[[Effect::Analysis enhancement]]''' - This effect is generally only present at low doses.
*'''[[Effect::Analysis enhancement]]''' - This effect is generally only present at low doses.
*'''[[Effect::Thought acceleration]]''' and '''[[Effect::Thought deceleration]]''' - Although one of 25C-NBOME's effects is thought acceleration, the opposite may occur at higher doses.
*'''[[Effect::Thought acceleration]]''' and '''[[Effect::Thought deceleration]]''' - Although one of 25C-NBOME's effects is thought acceleration, the opposite may occur at higher doses.
*'''[[Effect::Conceptual thinking]]''' - This effect is considered to be very mild compared to traditional psychedlics.
*'''[[Effect::Conceptual thinking]]''' - This effect is considered to be very mild compared to traditional psychedlics.
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect seems to occur more readily than other psychedelics, perhaps due to its very prominent stimulating properties
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect seems to occur more readily than other psychedelics, perhaps due to its very prominent stimulating properties
**'''[[Effect::Feelings of impending doom]]''' - This is generally only experienced during the comedown period or if one has taken a large amount of the substance.
*'''[[Effect::Feelings of impending doom]]''' - This is generally only experienced during the comedown period or if one has taken a large amount of the substance.
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - The [[entactogenic]] effects range from mild to powerful, but are inconsistently manifested. Entactogenic effects for people who try this substance usually become prominent in the presence of others. These feelings of increased sociability, love and empathy do not seem to be quite as strong or profound as those found within other [[entactogen|entactogens]] (such as [[MDMA]], [[2C-B]] and [[AMT]])
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - The [[entactogenic]] effects range from mild to powerful, but are inconsistently manifested. Entactogenic effects for people who try this substance usually become prominent in the presence of others. These feelings of increased sociability, love and empathy do not seem to be quite as strong or profound as those found within other [[entactogen|entactogens]] (such as [[MDMA]], [[2C-B]] and [[AMT]])
*'''[[Language suppression]]'''
*'''[[Language suppression]]'''
Line 130: Line 128:
}}
}}
{{effects/transpersonal|
{{effects/transpersonal|
While they are occasionally reported, the transpersonal effects produced by this substance seem to be significantly less consistent and reproducible than other [[psychedelics]], which perhaps corresponds with the mild alterations in the cognitive alterations it produces.  
Transpersonal effects on 25C-NBOMe are thought to occur with less frequency than classical psychedelics such as [[LSD]], [[psilocybin mushrooms]], and [[mescaline]].


*'''[[Effect::Existential self-realization]]'''
*'''[[Effect::Existential self-realization]]'''
Line 141: Line 139:
{{#ask: [[Category:25C-NBOMe]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:25C-NBOMe]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_25CNBOMe.shtml Erowid Experience Vaults: 25C-NBOMe]
 
*[https://www.erowid.org/experiences/subs/exp_25CNBOMe.shtml Erowid Experience Vaults: 25C-NBOMe]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{toxicity}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it can be [[Toxicity::fatal at heavy dosages]].<ref name="erowid">25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid - https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml</ref> 25C-NBOMe overdoses have also been linked to multi-organ failure.<ref>Fatal intoxication with the new designer drug 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26324189</ref><ref>Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890</ref>  
25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it can be [[Toxicity::fatal at heavy dosages]].<ref name="25Cfatal">{{Citation | title=Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml}}</ref><ref>{{cite journal | vauthors=((Tarpgaard, M.)), ((Mærkedahl, R.)), ((Lauridsen, K. B.)) | journal=Ugeskrift for Laeger | title=[Fatal intoxication with the new designer drug 25C-NBOMe] | volume=177 | issue=35 | pages=V09140523 | date=24 August 2015 | issn=1603-6824}}</ref><ref name="Grautoff2014">{{cite journal | vauthors=((Grautoff, S.)), ((Kähler, J.)) | journal=Medizinische Klinik, Intensivmedizin Und Notfallmedizin | title=[Near fatal intoxication with the novel psychoactive substance 25C-NBOMe] | volume=109 | issue=4 | pages=271–275 | date= May 2014 | issn=2193-6226 | doi=10.1007/s00063-014-0360-5}}</ref>
 
It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.<ref name="25Cfatal">{{Citation | title=Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml}}</ref><ref name="Grautoff2014"/>


It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.<ref>Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890</ref><ref name="erowid" />
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substances.
===Dependence and abuse potential===
25C-NBOMe is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating.  


===Tolerance and addiction potential===
Tolerance to the effects of 25C-NBOMe is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 25C-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25C-NBOMe all psychedelics will have a reduced effect.
25C-NBOMe is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.  


Tolerance to the effects of 25C-NBOMe are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 25C-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25C-NBOMe all psychedelics will have a reduced effect.
===Overdose===
{{NBOMeOD}}


===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/NBOMe}}


Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
==Legal status==


*'''[[Tramadol]]''' - Tramadol lowers the seizure threshold<ref>Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089</ref> and [[psychedelics]] may act as triggers for seizures, particularly in those who are predisposed to them.{{citation needed}}
*'''Austria''': Since June 26, 2019, 25C-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
*'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}
*'''Canada''': 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref>
*'''China''': As of October 2015 25C-NBOMe is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''Germany''': 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl114s1999.pdf%27%5D__1576023093735|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 11, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Anlage I BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref>
*'''Israel''': The NBOMe series of psychoactives became controlled in Israel in May, 2013.<ref name="ErowidNBOMEVault">{{Citation | title=Erowid NBOMe Series Vault : Legal Status | url=https://www.erowid.org/chemicals/nbome/nbome_law.shtml}}</ref>
*'''Italy''': 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref>
*'''Japan''': 25C-NBOMe is a narcotic drug in Japan effective November 1st, 2015.<ref>{{Citation | title=新たに4物質を麻薬に指定し、規制の強化を図ります |報道発表資料|厚生労働省 | publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)] | url=https://www.mhlw.go.jp/stf/houdou/0000098723.html | access-date=2 May 2022}}</ref>
*'''Latvia''': 25C-NBOMe is a Schedule I controlled substance.<ref>{{Citation | title=Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | url=https://likumi.lv/doc.php?id=121086}}</ref>
*'''New Zealand''': 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.<ref>{{Citation | year=2012 | title=“Legal high” DIME not so legal | url=https://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/}}</ref>
*'''Russia''': Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.<ref name="ErowidNBOMEVault" /><ref>Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html</ref>
*'''Sweden''': 25C-NBOMe is classed as Schedule I.<ref>{{Citation | title=Läkemedelsverkets författningssamling | url=https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter}}</ref>
*'''Switzerland''': 25C-NBOMe is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 25C-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf}}</ref>
*'''United Kingdom''': 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 | url=https://www.legislation.gov.uk/uksi/2014/1106/made}}</ref>
*'''United States''': Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.<ref>DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf</ref>


==Legality==
==See also==
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''Sweden:''' 25C-NBOMe is classed as Schedule I.<ref>Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf</ref>
*'''United Kingdom''' - 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref>
*'''Israel''' - The NBOMe series of psychoactives became controlled in Israel in May, 2013.<ref>https://www.erowid.org/chemicals/nbome/nbome_law.shtml</ref>
*'''New Zealand''' - 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.<ref>‘Legal high’ DIME not so legal | http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/</ref>
*'''Russia''' - Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.<ref>https://www.erowid.org/chemicals/nbome/nbome_law.shtml</ref><ref>Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html</ref>
*'''United States''' - Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.<ref>DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf</ref>
*'''China''' - As of October 2015 25C-NBOMe is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''Latvia:''' 25C-NBOMe is a Schedule I controlled substance.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''Canada:''' 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>


==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Psychedelics]]
*[[Psychedelics]]
Line 186: Line 192:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/25C-NBOMe 25C-NBOMe (Wikipedia)]
*[https://en.wikipedia.org/wiki/25C-NBOMe 25C-NBOMe (Wikipedia)]
*[https://erowid.org/chemicals/2cc_nbome/2cc_nbome.shtml 25C-NBOMe (Erowid Vault)]
*[https://erowid.org/chemicals/2cc_nbome/2cc_nbome.shtml 25C-NBOMe (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=343 25C-NBOMe (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=343 25C-NBOMe (Isomer Design)]
*[http://disregardeverythingisay.com/post/60874119182/25c-nbome-broken-down-and-described 25C-NBOMe (Disregard Everything I Say)]
*[https://drugs-forum.com/wiki/25C-NBOMe 25C-NBOMe (Drugs-Forum)]
 
===Discussion===
 
*[http://disregardeverythingisay.com/post/60874119182/25c-nbome-broken-down-and-described 25C-NBOMe, broken down and described (Disregard Everything I Say)]


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Psychedelic]]
[[Category:25x-NBOMe]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Phenethylamine]]
 
[[Category:Psychedelic]]
{{#set:Featured=true}}
{{#set:Featured=true
|RN=CH₂-C₆H₄-OCH₃
|Rα=
|Rβ=
|R2=
|R3=OCH₃
|R4=Cl
|R5=
|R6=OCH₃
}}